{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:28:07Z","timestamp":1794486487743,"version":"4.9.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In the phase 3 randomized SEQUOIA study (NCT03336333), zanubrutinib (arm A) demonstrated superior progression-free survival (PFS) compared with bendamustine-rituximab (BR; arm B) in patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) without del(17p). In the phase 3 AMPLIFY study (NCT03836261), acalabrutinib-venetoclax with or without obinutuzumab demonstrated prolonged PFS vs chemoimmunotherapy (investigator\u2019s choice of fludarabine, cyclophosphamide, and rituximab [FCR] or BR) in patients with treatment-naive CLL without del(17p) or TP53 mutations. Compared with AMPLIFY, the patient population in SEQUOIA was unsuitable for FCR and included patients with TP53 mutations. The aim of this post hoc analysis was to investigate the efficacy of zanubrutinib in patients from SEQUOIA vs a clinically similar patient population treated with acalabrutinib-venetoclax in AMPLIFY. A numerically greater 3-year investigator-assessed PFS (PFS-INV) was observed with zanubrutinib (84.3%) in the SEQUOIA population vs acalabrutinib-venetoclax in AMPLIFY (78.9%). When matching SEQUOIA to the AMPLIFY population by FCR eligibility, a greater PFS benefit with zanubrutinib was reported (89.2% vs 78.9%, respectively). To support the comparison of zanubrutinib vs acalabrutinib-venetoclax, an anchored matching-adjusted indirect comparison was performed, which showed that zanubrutinib was associated with prolonged PFS-INV vs acalabrutinib-venetoclax when adjusted for various baseline characteristics. Zanubrutinib also demonstrated longer PFS whether adjusted for age (PFS-INV hazard ratio [HR], 0.26; 95% confidence interval [CI], 0.13-0.54; P&amp;lt; .0003) or unadjusted (PFS-INV HR, 0.45; 95% CI, 0.23-0.88; P = .0197). These results highlight zanubrutinib monotherapy as an effective treatment option for all patients with treatment-naive CLL\/SLL, including patients who might otherwise be considered for more intensive fixed-duration combination regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018536","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T21:55:53Z","timestamp":1769464553000},"page":"2599-2607","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL"],"prefix":"10.1182","volume":"10","author":[{"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"3Lymphoma Service, Alfred Hospital, Melbourne, VIC"},{"name":"4Haematology Department, Monash University, Melbourne, VIC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"5Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lefebure","sequence":"additional","affiliation":[{"name":"6BeOne Medicines, Ltd, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"7BeOne Medicines, Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[{"name":"8BeOne Medicines, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"7BeOne Medicines, Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Kuptsova-Clarkson","sequence":"additional","affiliation":[{"name":"7BeOne Medicines, Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[{"name":"7BeOne Medicines, Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Hirata","sequence":"additional","affiliation":[{"name":"7BeOne Medicines, Ltd, San Carlos, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0769","authenticated-orcid":false,"given":"Talha","family":"Munir","sequence":"additional","affiliation":[{"name":"9Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"12","key":"2026042809465330700_bib1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"issue":"1","key":"2026042809465330700_bib2","doi-asserted-by":"crossref","first-page":"e2012067","DOI":"10.4084\/mjhid.2012.067","article-title":"Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL","volume":"4","author":"Efremov","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"2026042809465330700_bib3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2026042809465330700_bib4","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/cancers16112011","article-title":"Treatment sequencing in chronic lymphocytic leukemia in 2024: where we are and where we are headed","volume":"16","author":"Fresa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026042809465330700_bib5","volume-title":"Brukinsa. Prescribing information","year":"2025"},{"key":"2026042809465330700_bib6","volume-title":"Brukinsa. Summary of product characteristics","year":"2024"},{"issue":"6","key":"2026042809465330700_bib7","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1021\/acs.jmedchem.2c01938","article-title":"Discovery of BGB-8035, a highly selective covalent inhibitor of Bruton's tyrosine kinase for B-cell malignancies and autoimmune diseases","volume":"66","author":"Guo","year":"2023","journal-title":"J Med Chem"},{"issue":"11","key":"2026042809465330700_bib8","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","article-title":"Clinical pharmacology and PK\/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib","volume":"14","author":"Tam","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"25","key":"2026042809465330700_bib9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026042809465330700_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"2026042809465330700_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026042809465330700_bib12","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026042809465330700_bib13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026042809465330700_bib14","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"2026042809465330700_bib15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026042809465330700_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"issue":"6","key":"2026042809465330700_bib17","first-page":"1866","article-title":"Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison","volume":"109","author":"Al-Sawaf","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2026042809465330700_bib18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s10637-023-01376-1","article-title":"Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma","volume":"41","author":"Song","year":"2023","journal-title":"Invest New Drugs"},{"issue":"3","key":"2026042809465330700_bib19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence Technology Appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"22","key":"2026042809465330700_bib20","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"2026042809465330700_bib21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","author":"Al-Sawaf","year":"6  2025","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"2026042809465330700_bib24","doi-asserted-by":"crossref","first-page":"TPS7087","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7087","article-title":"CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-na\u00efve (TN) CLL","volume":"42","author":"Shadman","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"2026042809465330700_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1078-0432.CCR-23-2872","article-title":"Overcoming resistance in chronic lymphocytic leukemia-maybe less is more?","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026042809465330700_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2599\/2513803\/blooda_adv-2025-018536-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2599\/2513803\/blooda_adv-2025-018536-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:47:08Z","timestamp":1777384028000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/8\/2599\/566249\/An-indirect-comparison-of-zanubrutinib-vs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018536","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,28]]},"published":{"date-parts":[[2026,4,15]]}}}